| | 376653-43-9 Basic information More.. |
| Product Name: | Ceftobiprole medocaril | | Synonyms: | Ceftobiprole medocaril;5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylicacid,7-[[(2Z)-2-(5-aMino-1,2,4-thiadiazol-3-yl)-2-(hydroxyiMino)acetyl]aMino]-3-[[(E,3'R)-1'-[[(5-Methyl-2-oxo-1,3-dioxol-4-yl)Methoxy]carbonyl]-2-oxo[1,3'-bipyrrolidin]-3-ylidene]Methyl]-8-oxo-,(6R,7R)-;BAL5788;Ceftobiprole medocaril USP/EP/BP;5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylicacid,7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(hydroxyimino)acetyl]amino]-3-[[(E,3'R)-1'-[[(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy]carbonyl]-2-oxo[1;BAL-5788,Inhibitor,penicillin,cephalosporin,inhibit,gram-positive,pyrrolidinone,BAL 5788,MRSA,Ceftobiprole medocaril,Bacterial,vancomycin,pathogens,staphylococci,gram-negative,VRSA,methicillin,Prodrug;Valine Impurity 146 | | CAS: | 376653-43-9 | | MF: | C26H26N8O11S2 | | MW: | 690.66 | | EINECS: | | | Mol File: | 376653-43-9.mol |  |
Use
Ceftobiprole medocaril is a new injectable cephalosporin antibiotic with broad-spectrum activity against a wide range of difficult-to-treat Gram-positive and Gram-negative hospital- and community-acquired infections including MRSA. It was launched in Canada for the treatment of cSSSI, including diabetic foot infection.
- Ceftobiprole medocaril
-
- US $0.00-0.00 / Kg
- 2020-05-26
- CAS:376653-43-9
- Min. Order: 1KG
- Purity: 99.0%
- Supply Ability: 500 MT
|
|
376653-43-9
Recommend Suppliers |
|